G1 Therapeutics delays PhIII readout of lead drug — will cut 30% of staff, CFO to exit
G1 Therapeutics will lay off 30% of its workforce and replace its CFO as the biotech reports a Phase III trial readout delay.
Last month …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
